Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)

AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieterle, Thomas, Schaefer, Stefan, Meyer, Ina, Ackermann, Gabriele, Ahmed, Kashan, Hullin, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/
https://www.ncbi.nlm.nih.gov/pubmed/32369265
http://dx.doi.org/10.1002/ehf2.12716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/
https://www.ncbi.nlm.nih.gov/pubmed/32369265
http://dx.doi.org/10.1002/ehf2.12716

Ejemplares similares